Skip to main content
Top

Burden of status epilepticus: prognosis and cost driving factors, insight from a nationwide retrospective cohort study of the French health insurance database

Published in:

Abstract

Background

Status epilepticus (SE) imposes a significant burden in terms of in-hospital mortality and costs, but the relationship between SE causes, patient comorbidities, mortality, and cost remains insufficiently understood. We determined the in-hospital mortality and cost-driving factors of SE using a large and comprehensive database.

Methods

We conducted a retrospective cohort study involving patients experiencing their first hospitalization with an ICD-10 code diagnosis of SE, spanning from January 1, 2015, to December 31, 2019, using the French health insurance database which covers 99% of population. Patient characteristics, SE causes, Intensive Care Unit (ICU) admissions, mechanical ventilation, discharge status, and health insurance costs were extracted for each hospitalization.

Results

We identified 52,487 patients hospitalized for a first SE. In-hospital mortality occurred in 11,464 patients (21.8%), with associated factors including age (Odds Ratio [OR], 10.3, 95% Confidence Interval [CI] 7.87–13.8 for ages over 80 compared to 10–19), acute causes (OR, 15.3, 95% CI 13.9–16.8 for hypoxic cause), tumors (OR, 1.75, 95% CI 1.63–1.8), comorbidities (OR, 3.00, 95% CI 2.79–3.24 for 3 or more comorbidities compared to 0), and prolonged mechanical ventilation (OR, 2.61, 95% CI 2.42–2.82). The median reimbursed cost for each SE hospitalization was 6517€ (3364–13,354), with cost factors mirroring those of in-hospital mortality.

Conclusion

Causes and co-morbidities are major determinants of mortality and hospital costs in status epilepticus, and factors associated with higher mortality are also often associated with higher costs. Further studies are needed to identify their long-term effects.
Title
Burden of status epilepticus: prognosis and cost driving factors, insight from a nationwide retrospective cohort study of the French health insurance database
Authors
Quentin Calonge
François Le Gac
Mario Chavez
Adeline Degremont
Catherine Quantin
Florence Tubach
Sophie Tezenas du Montcel
Vincent Navarro
Publication date
23-08-2024
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 10/2024
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-024-12589-6
This content is only visible if you are logged in and have the appropriate permissions.
This content is only visible if you are logged in and have the appropriate permissions.

Keynote webinar | Spotlight on functional neurological disorder

FND perplexes and frustrates patients and physicians alike. Limited knowledge and insufficient awareness delays diagnosis and treatment, and many patients feel misunderstood and stigmatized. How can you recognize FND and what are the treatment options?

Prof. Mark Edwards
Watch now
Video

How can you integrate PET into your practice? (Link opens in a new window)

1.5 AMA PRA Category 1 Credit(s)™

PET imaging is playing an increasingly critical role in managing AD. Our expert-led program will empower you with practical strategies and real-world case studies to effectively integrate it into clinical practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Learn more
Image Credits
Human brain illustration/© (M) CHRISTOPH BURGSTEDT / SCIENCE PHOTO LIBRARY / Getty Images, Navigating neuroimaging in Alzheimer’s care: Practical applications and strategies for integration/© Springer Health+ IME